Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
Cancers · 11.01.2024 · 16 (2) · 318
DOI: 10.3390/cancers16020318 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.01.2024. Verfasst von Daniel Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco-Fresno Branch Campus, Fresno, CA 93701, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Locally advanced esophageal cancer (LAEC) poses a significant and persistent challenge in terms of effective treatment. Traditionally, the primary strategy for managing LAEC has involved concurrent neoadjuvant chemoradiation followed by surgery. However, achieving a pathologic complete response (pCR) has proven to be inconsistent, and despite treatment, roughly half of patients experience locoregional recurrence or metastasis. Consequently, there has been a paradigm shift towards exploring the potential of immunotherapy in reshaping the landscape of LAEC management. Recent research has particularly focused on immune checkpoint inhibitors, investigating their application in both neoadjuvant and adjuvant settings. These inhibitors, designed to block specific proteins in immune cells, are meant to enhance the immune system’s ability to target and combat cancer cells. Emerging evidence from these studies suggests the possibility of a mortality benefit, indicating that immunotherapy may contribute to improved overall survival rates for individuals grappling with esophageal cancer. This manuscript aims to meticulously review the existing literature surrounding neoadjuvant and adjuvant immunotherapy in the context of LAEC management. The intention is to thoroughly examine the methodologies and findings of relevant studies, providing a comprehensive synthesis of the current understanding of the impact of immunotherapy on esophageal cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California, San Francisco-Fresno Branch Campus, Fresno, CA 93701, USA.
- Loma Linda University Medical Center, Loma Linda, CA 92354, USA.
- Department of Internal Medicine for UCSF, University of California, and UC Riverside, Riverside, CA 92521, USA.
- City of Hope-Duarte, Department of Hematology & Oncology, Duarte, CA 91010, USA.
ORCID-Profile: Won Jin Jeon, Chieh Yang
Zitieren
APA
Park, D., Jeon, W. J., Yang, C., & Castillo, D. R. (2024). Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings. Cancers, 16(2), 318. https://doi.org/10.3390/cancers16020318
Vancouver
Park D, Jeon WJ, Yang C, Castillo DR. Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings. Cancers. 2024;16(2):318. doi:10.3390/cancers16020318
BibTeX
@article{Park2024,
author = {Park, Daniel and Jeon, Won Jin and Yang, Chieh and Castillo, Dani Ran},
title = {Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings},
journal = {Cancers},
year = {2024},
volume = {16},
number = {2},
pages = {318},
doi = {10.3390/cancers16020318}
}
EUVIMED